RxDoctor Payments Data

Arthur Menezes, MD

Interventional Cardiology · Tucson, AZNPI 1457670440

Payments from drug & device makers

$16,508in general payments, 2019–2025

Across 746 payments — averaging $22.13 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Kestra Medical Technology Services, Inc.$5K
  • Novartis$2K
  • ZOLL Services LLC (a/k/a ZOLL Lifecor Corp)$2K
  • Abbott$992
  • Actelion Pharmaceuticals US, Inc.$850
  • Johnson & Johnson$722
  • plus $5K from 32 others

What the payments were for

  • Consulting fees$1,4008%
  • Speaking & faculty fees$2,10013%
  • Food & beverage$12,85178%
  • Education$1581%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$16,508 in reported general payments places this provider in the 55th percentile of 223 interventional cardiology providers in Arizona.

See all interventional cardiology providers in Arizona

Medicare billing

Part B allowed, 2024
$282,972
Medicare patients
596
Services billed
3,323

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban527$573,906
XareltoRivaroxaban412$473,633
EntrestoSacubitril/Valsartan146$183,132
Repatha SureclickEvolocumab247$168,834
JardianceEmpagliflozin73$74,339
MultaqDronedarone Hcl39$53,831
FarxigaDapagliflozin Propanediol23$23,904
Clonidine158$20,791
Dabigatran EtexilateDabigatran Etexilate Mesylate54$16,442
Praluent PenAlirocumab28$14,766
Atorvastatin Calcium1,450$11,967
Metoprolol Succinate995$10,098
Chlorthalidone473$7,664
Potassium Chloride237$7,590
Losartan Potassium767$4,856

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$541$573,906527 claims
Johnson & JohnsonXarelto$722$473,633412 claims
NovartisEntresto$1,793$183,132146 claims
Boehringer IngelheimJardiance$286$74,33973 claims
Sanofi-aventis U.S. LLCMultaq$236$53,83139 claims
AstraZenecaFarxiga$208$23,90423 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 55th percentile of 223 interventional cardiology providers in Arizona.

Other interventional cardiology in Tucson

See the full list for Arizona

Where these figures come from

Is this you, or does something look wrong? →